---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-020751"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T14:00:40.895915+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics Q1 loss widens to $18.7M; PDUFA goal date August 29, 2023

## Summary
- Net loss $18.7M ($0.08/share) vs $14.5M ($0.08) in Q1 fiscal 2022.
- Cash and equivalents $52.3M; raised $24M equity and $30M convertible note in Dec 2022.
- FDA PDUFA goal date for ONS-5010 (wet AMD) set for August 29, 2023.
- Pre-launch commercial activities underway; partnership with AmerisourceBergen.
- EMA MAA accepted for ONS-5010; decision expected early 2024.

## SEC filing metadata
- accession: 0001104659-23-020751
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465923020751/0001104659-23-020751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465923020751/tm236701-1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-020751
- JSON: https://secwatch.observer/filing/0001104659-23-020751.json
- Plain text: https://secwatch.observer/filing/0001104659-23-020751.txt

## Key facts
- Earnings Releases
  Outlook Therapeutics, Inc. reported fiscal first quarter ended December 31, 2022 results: net income $18.7 million, or $0.08 per basic and diluted share, EPS $0.08 per basic and diluted share.
  - Period: fiscal first quarter ended December 31, 2022
  - Net income: $18.7 million, or $0.08 per basic and diluted share
  - EPS: $0.08 per basic and diluted share
  - Result: reported results
  source text: On February 14, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its first fiscal quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465923020751/0001104659-23-020751-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.